Clear cell adenocarcinoma
MONDO:0005004A malignant neoplasm composed of glandular epithelial clear cells. Various architectural patterns may be seen, including papillary, tubulocystic, and solid.
Also known as: adenocarcinoma, clear cell, malignant, clear cell adenocarcinoma, clear cell adenocarcinoma (morphologic abnormality), clear cell adenocarcinoma NOS (morphologic abnormality), mesonephroma NOS (morphologic abnormality), water-clear cell adenocarcinoma (morphologic abnormality), Wolffian duct neoplasm, clear cell carcinoma
2940 clinical trials for this condition and its sub-types, 14 tagged with Clear cell adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Clear cell adenocarcinoma
-
Clear cell renal carcinoma 140 trials · 142 incl. sub-types
2 sub-types
-
Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types
1 sub-type
-
Endometrial clear cell adenocarcinoma 21 trials
-
Fallopian tube clear cell adenocarcinoma 18 trials
-
Cervical clear cell adenocarcinoma 4 trials
1 sub-type
-
3 sub-types
-
Hidradenocarcinoma 1 trial
1 sub-type
- Vulvar clear cell hidradenocarcinoma 0 trials
-
1 sub-type
-
Hepatocellular clear cell carcinoma 0 trials
-
Immunotherapy combo shows promise against rare, tough ovarian cancer
Disease control OngoingThis study tests whether a combination of two immune-boosting drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell cancers of the ovary, fallopian tube, peritoneum, or other areas. About 46 participants will receive one of the two…
Phase 2 • Sponsor: Brown University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New PET scan could reveal kidney cancer drug success in weeks, not months
Diagnosis OngoingThis study tests whether a new type of PET scan using a radioactive antibody called 124I-cG250 can detect if kidney cancer is responding to targeted therapy (sunitinib or pazopanib) earlier than standard CT scans. The antibody attaches to a protein found on kidney cancer cells, m…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC